Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)
· seekingalpha.com
Capricor (CAPR) spikes on new deramiocel HOPE-3 24-month Duchenne data ahead of Nov.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...